Who Owns Beam Therapeutics Stock?
NASDAQ: BEAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 109.86%
- Institutions (% of float)
- 111.20%
- Held by insiders
- 1.20%
- Institutional holders
- 388
- Institutions 98.8%
- Insiders 1.2%
- Public and other 0.0%
Who owns Beam Therapeutics stock?
Institutional investors own about 109.9% of Beam Therapeutics's shares, spread across 388 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 1.20% of BEAM.
The largest institutional holders are FMR, LLC (12.49%), ARK Investment Management, LLC (11.41%) and Farallon Capital Management LLC (9.93%). Together, the top 10 institutions control 69.0% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their BEAM positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of BEAM
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FMR, LLC | 12.93M | 12.49% | +2.5% |
| ARK Investment Management, LLC | 11.81M | 11.41% | +15.3% |
| Farallon Capital Management LLC | 10.28M | 9.93% | +0.4% |
| Blackrock Inc. | 9.12M | 8.81% | +1.4% |
| State Street Corporation | 5.92M | 5.72% | +1.6% |
| Vanguard Portfolio Management LLC | 4.90M | 4.74% | -0.4% |
| Vanguard Capital Management LLC | 4.61M | 4.45% | +0.2% |
| Arch Venture Management, Llc | 4.54M | 4.39% | 0.0% |
| Kynam Capital Management, LP | 3.93M | 3.80% | +38.5% |
| Amova Asset Management Americas Inc | 3.35M | 3.24% | -3.1% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of BEAM
| Fund | Shares | % Held |
|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 6.21M | 6.00% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.46M | 3.34% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.44M | 3.33% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.27M | 3.16% |
| ARK ETF Trust-ARK Genomic Revolution ETF | 3.09M | 2.98% |
| iShares Trust-iShares Russell 2000 ETF | 2.57M | 2.48% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.36M | 2.28% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.36M | 1.31% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.14M | 1.10% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.09M | 1.05% |
Frequently asked questions
Who is the largest shareholder of Beam Therapeutics?
FMR, LLC is the largest institutional shareholder of BEAM, owning 12.49% of shares outstanding (12.93M shares) as of its latest 13F filing.
What percentage of Beam Therapeutics is owned by institutions?
Institutions own about 109.9% of BEAM shares and 111.2% of the public float.
How much of Beam Therapeutics do insiders own?
Insiders, such as officers and directors, own about 1.20% of BEAM shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.